A Multi-Center,Open-Label, Single-Arm, Multiple Dose Study With HOE901-U300 to Assess The Ease of Use And Safety of a New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Dec 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 14 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 02 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2015 to 1 Dec 2014.